With respect to mammary tumour latency, 25% of DMBA Only-treated PPARγ-WTs developed palpable tumours by week 15, whereas this trended toward week 21.5 in DMBA + ROSI-treated PPARγ-WT mice. The gene discussed is PPARG; the disease is breast cancer.